By Suherman Candra Maholtra 
The landscape of transfusion medicine has been fundamentally altered following the definitive identification of the genetic source of the AnWj blood group antigen. In a landmark study led by researchers at NHS Blood and Transplant (NHSBT) in Bristol, in collaboration with the International Blood Group Reference Laboratory (IBGRL) and the University of Bristol, scientists have officially established MAL as the 47th human blood group system. This discovery resolves a medical enigma that has persisted since 1972, providing a molecular blueprint for a marker that exists on the red blood cells of more than 99.9% of the global population. By pinpointing the MAL gene as the instructions for the protein carrying the AnWj antigen, the research team has equipped the global medical community with the tools necessary to identify rare individuals at risk of life-threatening transfusion reactions.
The breakthrough represents the culmination of decades of serological investigation and the application of cutting-edge genomic technologies. For over half a century, the AnWj antigen was a known entity in blood banks, yet its biological "home" remained invisible. The establishment of the MAL blood group system—now formally codified by the International Society of Blood Transfusion (ISBT) as ISBT 047—marks a significant milestone in the ongoing effort to map the immense complexity of human blood.
A Half-Century Search: The Origins of the AnWj Mystery
The story of the AnWj antigen began in 1972 when clinicians first identified a patient whose blood lacked a specific marker found in almost every other human being. In the specialized world of hematology, such markers are known as antigens—molecules on the surface of red blood cells that act as identification tags for the immune system. While the ABO and Rh systems are the most famous, the human body possesses hundreds of other antigens categorized into dozens of systems.
For fifty years, AnWj remained a "high-prevalence" antigen of unknown genetic origin. Because it is present in nearly the entire population, the vast majority of people are AnWj-positive. However, a minute fraction of the population is AnWj-negative. When these rare individuals are exposed to AnWj-positive blood—whether through transfusion or pregnancy—their immune systems may recognize the antigen as a foreign invader and produce antibodies to attack it.
The primary challenge in solving the AnWj puzzle was the scarcity of subjects. Inherited AnWj-negativity is one of the rarest blood phenotypes in existence. Throughout the decades, only a handful of individuals with the inherited form of the deficiency were identified, leaving researchers with a statistically insignificant pool of genetic material to study. This scarcity was compounded by the fact that AnWj-negativity can also be "acquired." Patients with certain hematological malignancies or specific cancers can see their AnWj expression suppressed, making it difficult for doctors to distinguish between a temporary medical condition and a permanent genetic trait.
The Role of Whole Exome Sequencing and Genomic Discovery
To bridge the gap between clinical observation and genetic proof, the research team turned to whole exome sequencing (WES). Unlike whole genome sequencing, which looks at the entire DNA strand, WES focuses specifically on the exons—the protein-coding regions of the genome. Since most known blood group antigens are located on proteins, the researchers hypothesized that the mutation responsible for AnWj-negativity would be found within these instructions.
The analysis led the team to the MAL gene, which encodes the Myelin and Lymphocyte (Mal) protein. The discovery was unexpected; while the Mal protein was known to be involved in membrane organization and cellular transport in other types of tissue, its presence and significance on the surface of red blood cells had not been previously characterized.
The researchers studied five individuals with the inherited AnWj-negative phenotype. This cohort included members of an Arab Israeli family and, most significantly, a blood sample provided in 2015 by the very woman who was first identified as AnWj-negative in the 1970s. The genomic data revealed that these individuals possessed homozygous deletions in the MAL gene. In genetic terms, "homozygous" means the individuals had inherited the defective or missing gene from both parents, resulting in a total absence of the Mal protein on their red blood cell membranes.
Experimental Validation: Proving the Link
Identifying a correlation between a gene and a blood type is only the first step; scientific rigor requires proof of causation. To confirm that the MAL gene was indeed responsible for the AnWj antigen, the team at the University of Bristol employed advanced gene manipulation techniques.
Using laboratory-grown cell lines, the researchers introduced a functional version of the MAL gene into cells that previously lacked it. Once the gene was expressed, the cells began to react with AnWj antibodies, effectively "turning on" the antigen. Conversely, when the researchers introduced the mutated versions of the gene found in AnWj-negative patients, the cells remained non-reactive.
Further experiments confirmed that the Mal protein was both "necessary and sufficient" for the expression of AnWj. This means that without the protein, the antigen cannot exist, and with the protein, the antigen is invariably present. This definitive evidence allowed the International Society of Blood Transfusion to ratify MAL as a unique blood group system.
Clinical Significance: Preventing Hemolytic Reactions
The discovery of the MAL system is not merely an academic triumph; it has immediate and profound implications for patient safety. When an AnWj-negative patient receives a transfusion of standard (AnWj-positive) blood, they are at risk of a hemolytic transfusion reaction. In such cases, the recipient’s antibodies bind to the donor’s red blood cells, triggering their destruction. This can lead to acute kidney failure, systemic shock, and in severe cases, death.
Historically, identifying these patients was a laborious process involving complex serological testing that could only be performed by specialized reference laboratories. With the identification of the MAL gene, blood centers can now develop high-throughput genotyping tests. These genetic screens can be integrated into existing platforms used to profile donors and patients, making it much easier to identify rare AnWj-negative donors across the globe.
The necessity of this work was highlighted in 2026 through several complex clinical cases. In one instance, a 75-year-old man with severe anemia was found to have an anti-AnWj autoantibody. Because compatible blood was unavailable, doctors had to proceed with an unmatched transfusion. Genetic testing later confirmed his MAL gene was normal, indicating his condition was acquired rather than inherited. In another 2026 case, a patient with B-cell lymphoma experienced red blood cell destruction after an incompatible transfusion. Clinicians successfully used sutimlimab—a monoclonal antibody that inhibits the C1s enzyme in the complement pathway—to manage the hemolysis. This marked the first reported use of the drug for anti-AnWj-associated complications, illustrating the evolving nature of treatment for rare blood types.
Chronology of a Breakthrough: 1972 to 2026
The timeline of the MAL discovery mirrors the evolution of modern genetics and hematology:
- 1972: The AnWj antigen is first described after a patient is found to lack a nearly universal blood marker.
- 1970s–2010s: For over 40 years, the antigen remains a "serological curiosity." Researchers identify that most cases are acquired due to illness, while inherited cases remain exceptionally rare.
- 2015: A key sample is collected from the original 1970s patient, providing a vital link for future genomic study.
- 2021–2023: The research team at NHSBT and the University of Bristol applies whole exome sequencing to inherited AnWj-negative samples, identifying the MAL gene.
- 2024: Laboratory validation through gene editing confirms the Mal protein carries the AnWj antigen.
- 2025–2026: The ISBT formally recognizes MAL as the 47th blood group system. During this same period, the JAMA system is announced as the 49th, highlighting a "golden age" of blood group discovery.
- 2026: Clinical reports emerge detailing the use of genotyping to differentiate between inherited and acquired AnWj-negativity and the use of complement inhibitors like sutimlimab to treat associated hemolysis.
Expert Reactions and the Human Element
The resolution of the AnWj mystery has drawn praise from the international scientific community. Louise Tilley, Senior Research Scientist at IBGRL, noted the personal weight of the discovery, stating that she had been working to resolve this specific mystery for nearly 20 years of her career. She emphasized that the breakthrough would not have been possible without the altruism of the rare patients who provided samples.
Ash Toye, Professor of Cell Biology at the University of Bristol, highlighted the synergy between clinical observation and laboratory science. He noted that the ability to manipulate gene expression in developing blood cells was the "smoking gun" needed to close a 50-year-old cold case in hematology.
Nicole Thornton, Head of IBGRL Red Cell Reference, underscored the global impact of the work. She pointed out that while the number of patients is small, the benefit to those individuals is immeasurable. The ability to design specific genotyping tests means that the "needle in a haystack" search for compatible blood can now be handled with molecular precision.
The Broader Impact on Modern Medicine
The identification of the MAL blood group system serves as a reminder of the hidden complexity of human biology. While the general public often thinks of blood in terms of four types (A, B, AB, and O), the reality is a vast array of molecular variations that define our biological individuality.
This discovery also highlights the shifting paradigm in transfusion medicine from serology (testing how blood reacts in a test tube) to genomics (testing the DNA directly). As genotyping becomes more affordable and accessible, the goal of "personalized transfusion medicine" moves closer to reality. For patients with rare types like MAL-negative, this means a future where compatible blood is not found by chance, but by a systematic, global database of genetically profiled donors.
Furthermore, the research into the Mal protein may open new doors in other fields. Since the protein is involved in membrane stability and is found in other tissues, understanding its role on the red blood cell could provide insights into how other cells organize their surfaces or respond to disease.
As the 47th blood group system, MAL stands as a testament to scientific persistence. It proves that even mysteries that span half a century can be solved through collaboration, technological innovation, and a dedication to the rare patients who often fall through the cracks of mainstream medical research. With the genetic map of human blood continuing to expand—as seen with the subsequent discovery of the JAMA system—the medical community is better prepared than ever to ensure that every transfusion is a safe one.
